· 自动抓取 · 最新研究  · 1 分钟阅读

Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy.

Bispecific T cell engagers (TCE) targeting BCMA or GPRC5D have improved outcomes in relapsed/refractory multiple myeloma (MM), yet up to 40% of patients are primarily refractory, and predictive biomar

Bispecific T cell engagers (TCE) targeting BCMA or GPRC5D have improved outcomes in relapsed/refractory multiple myeloma (MM), yet up to 40% of patients are primarily refractory, and predictive biomar

Bispecific T cell engagers (TCE) targeting BCMA or GPRC5D have improved outcomes in relapsed/refractory multiple myeloma (MM), yet up to 40% of patients are primarily refractory, and predictive biomarkers are scarce. To address this unmet clinical need, we developed an image-based, high-content ex vivo assay using patient-derived bone marrow mononuclear cells exposed to teclistamab or talquetamab. Multiplex immunofluorescence enabled single-cell quantification of plasma cell lysis, T cell expans


本文自动抓取自 PubMed,原文链接:Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy.

原文发布日期:2026-07-16

Related Posts

View All Posts »
异基因造血细胞移植后复发患者接受供者淋巴细胞输注的时机:单中心回顾性分析

异基因造血细胞移植后复发患者接受供者淋巴细胞输注的时机:单中心回顾性分析

供者淋巴细胞输注(DLI)是应对异基因造血干细胞移植(allo-HCT)后复发的重要策略。本研究回顾分析了2010至2022年间,83名在移植后复发并接受DLI的急性白血病或骨髓增生异常综合征(MDS)成年患者。通过每月检测嵌合度和基因标志物,将治疗分为“抢先治疗”(在分子复发时进行)和“常规治疗”(在明显的血液学复发时进行)。 生存分析表明,常规治疗组的生存率显著劣于抢先治疗组,其中常规治疗组